Form 8-K Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K


CURRENT REPORT

Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 18, 2011 


AGENUS INC.
(Exact name of registrant as specified in its charter)


DELAWARE

000-29089

06-1562417
(State or other jurisdiction
of incorporation)
(Commission File Number) (IRS Employer Identification No.)



3 Forbes Road
Lexington, MA

02421
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code:   781-674-4400



________________________________________________________________________________
(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    [   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    [   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    [   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    [   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

     On May 18, 2011, Agenus Inc. announced that new data from a Phase 2 trial testing the Prophage G-200 vaccine (HSPPC-96; vitespen) in recurrent glioma will be presented in a poster presentation at the 2011 ASCO Annual Meeting, which will be held in Chicago on June 3rd -7th. Full abstracts can now be viewed on the ASCO website www.chicago2011.asco.org.

     The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is furnished herewith:

      99.1 Press Release dated May 18, 2011


SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    AGENUS INC.
(Registrant)

May 18, 2011
(Date)
  /s/   SHALINI SHARP
Shalini Sharp
Chief Financial Officer



EXHIBIT INDEX

Exhibit No. Description of Exhibit

99.1 Press Release dated May 18, 2011